NovaBiotics' partnering discussions for nail antifungal boosted by positive Phase IIa data
This article was originally published in Scrip
Executive Summary
NovaBiotics' ongoing partnering discussions have been given a boost following the release of positive unblinded Phase IIa data for its lead product candidate Novexatin (NP-213), a treatment for fungal nail infection.